Rapid relief of radiotherapy-related neuropathic pain (RRNP) in head and neck cancer (HNC) survivors is challenging when relying solely on pharmacologic treatments, especially in the early stages of ...

Journavx is the first truly new painkiller approved by the Food and Drug Administration in more than 20 years. But the drug is expensive, and many people can't get it yet.

Investing.com -- Artelo Biosciences Inc (NASDAQ: ARTL) stock surged 10% following the presentation of positive preclinical data for its lead fatty acid binding protein 5 (FABP5) inhibitor, ART26.12, ...

SOLANA BEACH, Calif. - Artelo Biosciences, Inc. (NASDAQ:ARTL), a micro-cap biotech company with a market capitalization of $10.87 million, presented preclinical data for its fatty acid binding protein ...

Aktien » Nachrichten » ARTELO BIOSCIENCES AKTIE » Artelo Biosciences Announces Positive Preclinical Efficacy Data for ART26.12 in Osteoarthritis Pain at the 35th Annual International ...

Artelo Biosciences presents preclinical data showing its FABP5 inhibitor ART26.12 alleviates osteoarthritis pain during the ICRS Symposium.